AUTHORS
Sandeep Sunder Raj, MD, Rou-En Joan Choo2, Karthik Nath, PhD, MBBS3, Teng Fei, PhD4, Alexander P. Boardman, MD5, Ana Alarcón Tomás6, Michael Scordo, MD7, Gunjan L. Shah, MD, MS8, Craig Sauter, MD9, Maria Lia Palomba, MD10, Parastoo B. Dahi, MD11, Richard J. Lin, MD, PhD12, Elena Mead13, Andrei Holodny, MD14, Andre Goy, MD15, Roni Shouval Jr, MD, PhD16, Bianca Santomasso, MD, PhD17, Renier Brentjens, MD, PhD18, Lori A Leslie, MD19, Gilles Salles I, MD, PhD20, Miguel-Angel Perales, MD21, Michel Sadelain, MD, PhD22, Jae H Park, MD23
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 John Theurer Cancer Center, Hackensack, New Jersey, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
19 John Theurer Cancer Center, Hackensack, New Jersey, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Columbia University Irving Medical Center, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Background: Systemic inflammation is a driver of immune toxicity and CAR-T treatment failure in non-Hodgkin lymphoma (NHL). Preclinical evidence showed that anti-inflammatory prophylaxis through IL-1 inhibition with anakinra can reduce immune effector cell-associated neurotoxicity syndrome (ICANS). We evaluated this strategy in a phase II clinical trial of patients with B-cell lymphomas receiving CD19-diected CAR-T therapy. We previously reported results from Cohort 1 of this study in an interim analysis reporting a low rate of severe ICANS. Here, we report the final study results, including findings from Cohort 2 where a complete prophylactic strategy was utilized with earlier anakinra initiation on the day of infusion.
Methods: In this single-arm, phase II interventional trial, we investigated prophylactic anakinra to reduce severe (grade ≥ 3) ICANS in recipients of commercial CD19 CAR T-cell therapy for B-cell lymphoma in two independent cohorts. Treatment schedule was subcutaneous anakinra 100mg twice daily between days 2 and 10 in Cohort 1 (n=31) and 100mg daily between days 0 and 7 in Cohort 2 (n=30). Both cohorts included prompt risk-adapted anakinra dose-escalation. In a post-hoc analysis, we identified a control cohort using 1:1 propensity-score matching to a real-world database of 246 patients with B-cell lymphomas treated with CAR-T without anakinra prophylaxis and who met trial eligibility during the trial period. Patients were matched on age, performance status, baseline LDH, disease response at infusion, CAR-T costimulatory domain, and lymphoma subtype. Sensitivity analyses were conducted using inverse probability treatment weighting as an alternative matching algorithm and adding CRP and CNS disease as matching variables. Longitudinal plasma proteomic profiling was performed across both treatment and control cohorts and analyzed with linear mixed effects modeling. All regression analyses comparing treatment versus control cohorts accounted for matching between patient pairs.
Results: Among 61 patients with large B-cell (75%), mantle cell (15%), or follicular lymphoma (10%) treated on study, 69% received axi-cel, 15% brexu-cel, 9% tisacel, and 7% liso-cel. Severe ICANS (grade ≥ 3) was 10% (3/30) in Cohort 2, similar to Cohort 1(9.7%; 3/31) and lower than historic controls (~25%); restricting to CD28 CAR-T products showed the same pattern, with rates of 11% in Cohort 1 and 12.5% in Cohort 2 versus ~30% in historic controls.
In the matched analysis, anakinra was associated with significantly lower odds of severe ICANS (OR 0.23, 95% CI 0.07-0.81; p=0.02). There was no significant difference in rates of cytokine release syndrome (CRS), but anakinra was associated with higher rates of early immune effector cell-associated hematotoxicity (ICAHT; OR 3.20 95% CI 1.17-8.73; p=0.02). In efficacy analyses, anakinra was associated with higher odds of remaining in CR at 1 year (OR 2.67, 95% CI 1.04-6.81; p=0.04), improved PFS (HR 0.50, 95% CI 0.27-0.91; p=0.02), and lower relapse incidence (HR 0.50, 95% CI 0.27-0.93; p=0.03). Findings were robust across multiple propensity model specifications. PFS benefit was greater in patients with higher baseline inflammation as measured by CRP (p < 0.05). Post-infusion ALC increased more in anakinra treated patients (p < 0.05).
Compared with Cohort 1, Cohort 2 had an earlier dosing schedule and a higher rate of anakinra dose escalation (77% vs 48%). This resulted in higher and earlier cumulative anakinra exposure in Cohort 2. In exploratory analyses, Cohort 2 showed a greater PFS benefit in inflamed patients and had post-infusion cytokine profiles more strongly enriched for T-cell activation (i.e., IL-2, IFN-γ, and NF-κB signaling) compared to those in Cohort 1.
Conclusions: In this prospective clinical trial, anakinra prophylaxis resulted in lower rates of severe ICANS after CD19 CAR-T compared with historical controls. In post hoc causal inference analyses, anakinra prophylaxis also correlated with less severe ICANS and improved CAR-T efficacy, particularly in patients with higher baseline inflammation. Treatment effect was greater with earlier and higher cumulative anakinra dosing, highlighting the importance of timing and adequate dosing. These data are the first to show a benefit for targeting inflammation to improve the therapeutic index of CAR-T therapy in lymphoma, inviting further prospective evaluation of anakinra prophylaxis in cellular therapy.
DISCLOSURES
Sandeep Sunder Raj, MD: No relevant conflicts of interest to declare.